Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Cross-Talk between Receptor Tyrosine Kinases AXL and ERBB3 Regulates Invadopodia Formation in Melanoma Cells.

Revach OY, Sandler O, Samuels Y, Geiger B.

Cancer Res. 2019 May 15;79(10):2634-2648. doi: 10.1158/0008-5472.CAN-18-2316. Epub 2019 Mar 26.

PMID:
30914429
2.

Exome Sequencing of ABCB5 Identifies Recurrent Melanoma Mutations that Result in Increased Proliferative and Invasive Capacities.

Sana G, Madigan JP, Gartner JJ, Fourrez M, Lin J, Qutob N, Narayan J, Shukla S, Ambudkar SV, Xia D, Rosenberg SA, Gottesman MM, Samuels Y, Gillet JP.

J Invest Dermatol. 2019 Mar 21. pii: S0022-202X(19)31330-2. doi: 10.1016/j.jid.2019.01.036. [Epub ahead of print]

3.

Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y.

Oncotarget. 2019 Feb 12;10(13):1344. doi: 10.18632/oncotarget.26685. eCollection 2019 Feb 12.

4.

Author Correction: Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.

Arafeh R, Flores K, Keren-Paz A, Maik-Rachline G, Gutkind N, Rosenberg S, Seger R, Samuels Y.

Sci Rep. 2019 Mar 12;9(1):4672. doi: 10.1038/s41598-018-37931-7.

5.

Author Correction: RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezki A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, Scolyer RA, Martemyanov KA, Samuels Y.

Sci Rep. 2019 Mar 9;9(1):4523. doi: 10.1038/s41598-018-37932-6.

6.

PIK3CA in cancer: The past 30 years.

Arafeh R, Samuels Y.

Semin Cancer Biol. 2019 Feb 10. pii: S1044-579X(18)30152-4. doi: 10.1016/j.semcancer.2019.02.002. [Epub ahead of print] Review.

PMID:
30742905
7.

Cancer research in the era of immunogenomics.

Wolf Y, Samuels Y.

ESMO Open. 2018 Dec 26;3(7):e000475. doi: 10.1136/esmoopen-2018-000475. eCollection 2018. Review.

8.

RASA2 and NF1; two-negative regulators of Ras with complementary functions in melanoma.

Arafeh R, Di Pizio A, Elkahloun AG, Dym O, Niv MY, Samuels Y.

Oncogene. 2019 Mar;38(13):2432-2434. doi: 10.1038/s41388-018-0578-4. Epub 2018 Nov 26. No abstract available.

PMID:
30478445
9.

Cancer Exome-Based Identification of Tumor Neo-Antigens Using Mass Spectrometry.

Kalaora S, Samuels Y.

Methods Mol Biol. 2019;1884:203-214. doi: 10.1007/978-1-4939-8885-3_14.

PMID:
30465205
10.

Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.

Kalaora S, Wolf Y, Feferman T, Barnea E, Greenstein E, Reshef D, Tirosh I, Reuben A, Patkar S, Levy R, Quinkhardt J, Omokoko T, Qutob N, Golani O, Zhang J, Mao X, Song X, Bernatchez C, Haymaker C, Forget MA, Creasy C, Greenberg P, Carter BW, Cooper ZA, Rosenberg SA, Lotem M, Sahin U, Shakhar G, Ruppin E, Wargo JA, Friedman N, Admon A, Samuels Y.

Cancer Discov. 2018 Nov;8(11):1366-1375. doi: 10.1158/2159-8290.CD-17-1418. Epub 2018 Sep 12.

11.

CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma.

Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y.

Oncotarget. 2018 Jul 27;9(58):31264-31277. doi: 10.18632/oncotarget.25805. eCollection 2018 Jul 27. Erratum in: Oncotarget. 2019 Feb 12;10(13):1344.

12.

Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures.

Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, Keshet R, Stettner N, Silberman A, Agemy L, Helbling D, Eilam R, Sun Q, Brandis A, Malitsky S, Itkin M, Weiss H, Pinto S, Kalaora S, Levy R, Barnea E, Admon A, Dimmock D, Stern-Ginossar N, Scherz A, Nagamani SCS, Unda M, Wilson DM 3rd, Elhasid R, Carracedo A, Samuels Y, Hannenhalli S, Ruppin E, Erez A.

Cell. 2018 Sep 6;174(6):1559-1570.e22. doi: 10.1016/j.cell.2018.07.019. Epub 2018 Aug 9.

PMID:
30100185
13.

Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.

Martin D, Degese MS, Vitale-Cross L, Iglesias-Bartolome R, Valera JLC, Wang Z, Feng X, Yeerna H, Vadmal V, Moroishi T, Thorne RF, Zaida M, Siegele B, Cheong SC, Molinolo AA, Samuels Y, Tamayo P, Guan KL, Lippman SM, Lyons JG, Gutkind JS.

Nat Commun. 2018 Jul 9;9(1):2372. doi: 10.1038/s41467-018-04590-1.

14.

Harnessing synthetic lethality to predict the response to cancer treatment.

Lee JS, Das A, Jerby-Arnon L, Arafeh R, Auslander N, Davidson M, McGarry L, James D, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, Stein G, Waterfall JJ, Meltzer PS, Golan T, Hannenhalli S, Gottlieb E, Benes CH, Samuels Y, Shanks E, Ruppin E.

Nat Commun. 2018 Jun 29;9(1):2546. doi: 10.1038/s41467-018-04647-1.

15.

Mutated MITF-E87R in Melanoma Enhances Tumor Progression via S100A4.

Nordlinger A, Dror S, Elkahloun A, Del Rio J, Stubbs E, Golan T, Malcov H, Pricket TD, Cronin JC, Parikh S, Labes S, Thomas L, Yankovitz G, Tabach Y, Levy C, Samuels Y, Khaled M.

J Invest Dermatol. 2018 Oct;138(10):2216-2223. doi: 10.1016/j.jid.2018.03.1524. Epub 2018 Apr 19.

PMID:
29679610
16.

Refinement of the endogenous epitope tagging technology allows the identification of a novel NRAS binding partner in melanoma.

Alon M, Emmanuel R, Qutob N, Bakhman A, Peshti V, Brodezki A, Bassan D, Kosloff M, Samuels Y.

Pigment Cell Melanoma Res. 2018 Sep;31(5):641-648. doi: 10.1111/pcmr.12705. Epub 2018 May 16.

17.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Apr 9;33(4):785. doi: 10.1016/j.ccell.2018.03.009. No abstract available.

18.

Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.

Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, Li L, Dhawan D, Meierjohann S, Reimann M, Elkahloun A, Treitschke S, Dörken B, Speck C, Mallette FA, Zon LI, Holmen SL, Peeper DS, Samuels Y, Schmitt CA, Lee S.

Cancer Cell. 2018 Feb 12;33(2):322-336.e8. doi: 10.1016/j.ccell.2018.01.002. Erratum in: Cancer Cell. 2018 Apr 9;33(4):785.

19.

RGS7 is recurrently mutated in melanoma and promotes migration and invasion of human cancer cells.

Qutob N, Masuho I, Alon M, Emmanuel R, Cohen I, Di Pizio A, Madore J, Elkahloun A, Ziv T, Levy R, Gartner JJ, Hill VK, Lin JC, Hevroni Y, Greenberg P, Brodezki A, Rosenberg SA, Kosloff M, Hayward NK, Admon A, Niv MY, Scolyer RA, Martemyanov KA, Samuels Y.

Sci Rep. 2018 Jan 12;8(1):653. doi: 10.1038/s41598-017-18851-4. Erratum in: Sci Rep. 2019 Mar 9;9(1):4523.

20.

Analysis of Enzymatic Activity of Matrix Metalloproteinase (MMP) by Collagen Zymography in Melanoma.

Walia V, Samuels Y.

Methods Mol Biol. 2018;1731:97-106. doi: 10.1007/978-1-4939-7595-2_10.

PMID:
29318547
21.

Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.

Arafeh R, Flores K, Keren-Paz A, Maik-Rachline G, Gutkind N, Rosenberg S, Seger R, Samuels Y.

Sci Rep. 2017 Nov 27;7(1):16345. doi: 10.1038/s41598-017-16558-0. Erratum in: Sci Rep. 2019 Mar 12;9(1):4672.

22.

Genetic and Functional Analysis of GRIN2A in Tumor Samples.

Prickett TD, Gartner JJ, Samuels Y.

Methods Mol Biol. 2017;1677:93-116. doi: 10.1007/978-1-4939-7321-7_3.

PMID:
28986867
23.

Synonymous Somatic Variants in Human Cancer Are Not Infamous: A Plea for Full Disclosure in Databases and Publications.

Soussi T, Taschner PE, Samuels Y.

Hum Mutat. 2017 Apr;38(4):339-342. doi: 10.1002/humu.23163. Epub 2017 Feb 2.

PMID:
28026089
24.

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.

Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, Jin Z, Dong B, Cao B, Feng X, Xiang M, Xu C, Fink S, Meropol NJ, Xu Y, Conlon RA, Markowitz S, Kinzler KW, Velculescu VE, Brunengraber H, Willis JE, LaFramboise T, Hatzoglou M, Zhang GF, Vogelstein B, Wang Z.

Nat Commun. 2016 Jun 20;7:11971. doi: 10.1038/ncomms11971.

25.

Parkin Somatic Mutations Link Melanoma and Parkinson's Disease.

Levin L, Srour S, Gartner J, Kapitansky O, Qutob N, Dror S, Golan T, Dayan R, Brener R, Ziv T, Khaled M, Schueler-Furman O, Samuels Y, Levy C.

J Genet Genomics. 2016 Jun 20;43(6):369-79. doi: 10.1016/j.jgg.2016.05.005. Epub 2016 May 13.

PMID:
27297116
26.

Parkinson disease (PARK) genes are somatically mutated in cutaneous melanoma.

Inzelberg R, Samuels Y, Azizi E, Qutob N, Inzelberg L, Domany E, Schechtman E, Friedman E.

Neurol Genet. 2016 Apr 13;2(3):e70. doi: 10.1212/NXG.0000000000000070. eCollection 2016 Jun.

27.

The involvement of mutant Rac1 in the formation of invadopodia in cultured melanoma cells.

Revach OY, Winograd-Katz SE, Samuels Y, Geiger B.

Exp Cell Res. 2016 Apr 10;343(1):82-88. doi: 10.1016/j.yexcr.2016.02.003. Epub 2016 Feb 10. Review.

28.

Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens.

Kalaora S, Barnea E, Merhavi-Shoham E, Qutob N, Teer JK, Shimony N, Schachter J, Rosenberg SA, Besser MJ, Admon A, Samuels Y.

Oncotarget. 2016 Feb 2;7(5):5110-7. doi: 10.18632/oncotarget.6960.

29.

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JJ, Curry WT, Zhao D, Sundaram S, Nigim F, Koerner MVA, Ho Q, Fisher DE, Roider EM, Kemeny LV, Samuels Y, Flaherty KT, Batchelor TT, Chi AS, Cahill DP.

Cancer Cell. 2015 Dec 14;28(6):773-784. doi: 10.1016/j.ccell.2015.11.006.

30.

Recurrent inactivating RASA2 mutations in melanoma.

Arafeh R, Qutob N, Emmanuel R, Keren-Paz A, Madore J, Elkahloun A, Wilmott JS, Gartner JJ, Di Pizio A, Winograd-Katz S, Sindiri S, Rotkopf R, Dutton-Regester K, Johansson P, Pritchard AL, Waddell N, Hill VK, Lin JC, Hevroni Y, Rosenberg SA, Khan J, Ben-Dor S, Niv MY, Ulitsky I, Mann GJ, Scolyer RA, Hayward NK, Samuels Y.

Nat Genet. 2015 Dec;47(12):1408-10. doi: 10.1038/ng.3427. Epub 2015 Oct 26.

31.

The functional relevance of somatic synonymous mutations in melanoma and other cancers.

Gotea V, Gartner JJ, Qutob N, Elnitski L, Samuels Y.

Pigment Cell Melanoma Res. 2015 Nov;28(6):673-84. doi: 10.1111/pcmr.12413. Review.

32.

Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation.

Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, Wargo JA, Dummer R, Flaherty KT, Ronai ZA.

Cell Rep. 2015 Jun 9;11(9):1458-73. doi: 10.1016/j.celrep.2015.04.049. Epub 2015 May 28.

33.

YAP and the drug resistance highway.

Keren-Paz A, Emmanuel R, Samuels Y.

Nat Genet. 2015 Mar;47(3):193-4. doi: 10.1038/ng.3228.

34.

The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.

Martin D, Abba MC, Molinolo AA, Vitale-Cross L, Wang Z, Zaida M, Delic NC, Samuels Y, Lyons JG, Gutkind JS.

Oncotarget. 2014 Oct 15;5(19):8906-23.

35.

Mutational and functional analysis of the tumor-suppressor PTPRD in human melanoma.

Walia V, Prickett TD, Kim JS, Gartner JJ, Lin JC, Zhou M, Rosenberg SA, Elble RC, Solomon DA, Waldman T, Samuels Y.

Hum Mutat. 2014 Nov;35(11):1301-10. doi: 10.1002/humu.22630. Epub 2014 Sep 10.

36.

Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF.

Clin Cancer Res. 2014 Jul 1;20(13):3401-10. doi: 10.1158/1078-0432.CCR-14-0433.

37.

A highly recurrent RPS27 5'UTR mutation in melanoma.

Dutton-Regester K, Gartner JJ, Emmanuel R, Qutob N, Davies MA, Gershenwald JE, Robinson W, Robinson S, Rosenberg SA, Scolyer RA, Mann GJ, Thompson JF, Hayward NK, Samuels Y.

Oncotarget. 2014 May 30;5(10):2912-7.

38.

Somatic mutation of GRIN2A in malignant melanoma results in loss of tumor suppressor activity via aberrant NMDAR complex formation.

Prickett TD, Zerlanko BJ, Hill VK, Gartner JJ, Qutob N, Jiang J, Simaan M, Wunderlich J, Gutkind JS, Rosenberg SA, Samuels Y.

J Invest Dermatol. 2014 Sep;134(9):2390-2398. doi: 10.1038/jid.2014.190. Epub 2014 Apr 16.

39.

ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

Lau C, Killian KJ, Samuels Y, Rudloff U.

Methods Mol Biol. 2014;1102:461-80. doi: 10.1007/978-1-62703-727-3_24.

40.

Somatic mutations in MAP3K5 attenuate its proapoptotic function in melanoma through increased binding to thioredoxin.

Prickett TD, Zerlanko B, Gartner JJ, Parker SCJ, Dutton-Regester K, Lin JC, Teer JK, Wei X, Jiang J, Nisc Comparative Sequencing Program, Chen G, Davies MA, Gershenwald JE, Robinson W, Robinson S, Hayward NK, Rosenberg SA, Margulies EH, Samuels Y.

J Invest Dermatol. 2014 Feb;134(2):452-460. doi: 10.1038/jid.2013.365. Epub 2013 Sep 5.

41.

Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma.

Gartner JJ, Parker SC, Prickett TD, Dutton-Regester K, Stitzel ML, Lin JC, Davis S, Simhadri VL, Jha S, Katagiri N, Gotea V, Teer JK, Wei X, Morken MA, Bhanot UK; NISC Comparative Sequencing Program, Chen G, Elnitski LL, Davies MA, Gershenwald JE, Carter H, Karchin R, Robinson W, Robinson S, Rosenberg SA, Collins FS, Parmigiani G, Komar AA, Kimchi-Sarfaty C, Hayward NK, Margulies EH, Samuels Y.

Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13481-6. doi: 10.1073/pnas.1304227110. Epub 2013 Jul 30. Erratum in: Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):563.

42.

The genetics of melanoma: recent advances.

Hill VK, Gartner JJ, Samuels Y, Goldstein AM.

Annu Rev Genomics Hum Genet. 2013;14:257-79. doi: 10.1146/annurev-genom-091212-153429. Epub 2013 Jul 12. Review.

PMID:
23875803
43.

Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression.

Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF.

J Immunol. 2013 Jun 15;190(12):6034-42. doi: 10.4049/jimmunol.1202830. Epub 2013 May 20.

44.

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, Samuels Y, Rosenberg SA.

Nat Med. 2013 Jun;19(6):747-52. doi: 10.1038/nm.3161. Epub 2013 May 5.

45.

Shimmer: detection of genetic alterations in tumors using next-generation sequence data.

Hansen NF, Gartner JJ, Mei L, Samuels Y, Mullikin JC.

Bioinformatics. 2013 Jun 15;29(12):1498-503. doi: 10.1093/bioinformatics/btt183. Epub 2013 Apr 24.

46.

Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma.

Gartner JJ, Davis S, Wei X, Lin JC, Trivedi NS, Teer JK; NISC Comparative Sequencing Program, Meltzer PS, Rosenberg SA, Samuels Y.

BMC Genomics. 2012 Sep 24;13:505. doi: 10.1186/1471-2164-13-505.

47.

Mutational signatures of de-differentiation in functional non-coding regions of melanoma genomes.

Parker SC, Gartner J, Cardenas-Navia I, Wei X, Ozel Abaan H, Ajay SS, Hansen NF, Song L, Bhanot UK, Killian JK, Gindin Y, Walker RL, Meltzer PS, Mullikin JC, Furey TS, Crawford GE, Rosenberg SA, Samuels Y, Margulies EH.

PLoS Genet. 2012;8(8):e1002871. doi: 10.1371/journal.pgen.1002871. Epub 2012 Aug 9.

48.

Molecular pathways: dysregulated glutamatergic signaling pathways in cancer.

Prickett TD, Samuels Y.

Clin Cancer Res. 2012 Aug 15;18(16):4240-6. doi: 10.1158/1078-0432.CCR-11-1217. Epub 2012 May 30. Review.

49.

Delving into somatic variation in sporadic melanoma.

Walia V, Mu EW, Lin JC, Samuels Y.

Pigment Cell Melanoma Res. 2012 Mar;25(2):155-70. doi: 10.1111/j.1755-148X.2012.00976.x. Epub 2012 Feb 13. Review.

50.

Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma.

Prickett TD, Wei X, Cardenas-Navia I, Teer JK, Lin JC, Walia V, Gartner J, Jiang J, Cherukuri PF, Molinolo A, Davies MA, Gershenwald JE, Stemke-Hale K, Rosenberg SA, Margulies EH, Samuels Y.

Nat Genet. 2011 Sep 25;43(11):1119-26. doi: 10.1038/ng.950.

Supplemental Content

Loading ...
Support Center